Feasibility Study of the Hemolung Respiratory Assist System
A Prospective, Non-Randomized Feasibility Study of the Hemolung Respiratory Assist System in COPD Patients With Acute Respiratory Failure That Are at a 50% Risk of Failing Non Invasive Ventilation (NIV)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Haryana
-
Gurgaon, Haryana, India, 122001
- Artemis Health Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Moderate or severe COPD, as defined by the GOLD criteria
- Acute exacerbation of COPD (sustained worsening of patient's condition necessitating a change in regular medication)
- On non-invasive positive pressure mechanical ventilation > 1hour with either:
- PaCO2 > 55 mmHg with pH < 7.25 OR
- PaCO2 > 55 mmHg with < 5mmHg decrease from baseline and pH < 7.30
- Not severely hypoxemic (PaO2/FiO2 ≥ 200 mmHg on PEEP/CPAP ≤ 5 cmH2O)
- Hemodynamically stable (mean arterial pressure > 65 mmHg without vasopressor support)
- Chronic arrhythmias (e.g., atrial fibrillation) well controlled
- Minimum platelet count of 100,000/mm3
- Minimum red blood cell count of 2.5 mill/μl
Exclusion Criteria:
- Presence of acute, uncontrolled arrhythmia
- Acute ischemic heart disease
- Presence of bleeding diathesis
- Significant abnormality or weakness/paralysis of respiratory muscles due to a know muscular dystrophy or neurologic disorder
- Recent (< 7 days) prolonged (>24 hrs) use of muscle paralyzing agents
- Cerebrovascular accident, intracranial bleed, head injury or other neurologic disorder likely to affect ventilation
- Coma from any cause, or decreased consciousness
- Hypersensitivity to heparin or previous heparin induced thrombocytopenia
- Recent (< 6 months) major chest abdominal trauma or surgery
- Presence of septic shock
- Presence of a significant pneumothorax or bronchopleural fistula
- History of uncontrolled major psychiatric disorder
- Pregnant women
- Known to have AIDS or to have symptomatic HIV
- Received chemotherapy or radiation within the previous 90 days
- Received an organ transplant other than corneal transplants
- Received or currently receiving immunosuppressive therapy, excluding corticosteroids within the last 3 months
- Presence of severe renal or liver failures
- Known vascular abnormality with could complicate or prevent successful insertion of the vascular access catheter in the right femoral vein
- Presence of another catheter in the right femoral vein that cannot be moved
- Presence of an inferior vena cava filter
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Hemolung Respiratory Assist System
|
Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System.
Patients will be weaned from non-invasive ventilation and then the Hemolung.
Hemolung support will be provided for up to 7 days.
Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Frequency of occurrence of serious adverse events while on Hemolung therapy and up to 30 days after cessation of therapy and decannulation.
Time Frame: 30 days
|
30 days
|
|
Percentage of patients requiring Mechanical Ventilation
Time Frame: 7 days
|
7 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Improvement in patient self assessment of dyspnea using visual analog scale pre- to post-Hemolung therapy.
Time Frame: 7 days
|
7 days
|
|
Change in Minute Volume (VE) pre- to end-Hemolung therapy
Time Frame: 7 days
|
7 days
|
|
Number of days in the ICU
Time Frame: 30 days
|
30 days
|
|
Number of days in the hospital
Time Frame: 30 days
|
30 days
|
|
Number of days alive and off mechanical ventilation for > 48 hours through the end of Day 30 following completion of Hemolung therapy
Time Frame: 30 days
|
30 days
|
|
Percentage of patients requiring sedation, and hours of sedation
Time Frame: 30 days
|
30 days
|
|
Number of days on Non-Invasive Positive Pressure Ventilation (NIPPV)
Time Frame: 30 days
|
30 days
|
|
For patients requiring Mechanical Ventilation, number of days on Mechanical Ventilation
Time Frame: 30 days
|
30 days
|
|
Duration of weaning time from NIPPV
Time Frame: 7 days
|
7 days
|
|
Duration of weaning time from Hemolung therapy
Time Frame: 7 days
|
7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: RK Mani, MD, Artemis Health Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HL-CA-2000
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.